Adults 18 to 50, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Specificity of ORI to Detect Drops in OxygenationPrimary· 1-5 hours per subject
A measure of the ORI parameter's ability to detect changes in dissolved oxygen levels in blood plasma. Specificity, as measured in this outcome, is the probability of ORI not dropping when there is no drop in blood oxygen levels (desaturation).
PaO2 Threshold: 110 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
98.50
PaO2 Threshold: 120 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
96.68
PaO2 Threshold: 130 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
98.89
PaO2 Threshold: 140 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
96.95
PaO2 Threshold: 150 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
97.67
PaO2 Threshold: 160 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
94.75
PaO2 Threshold: 170 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
93.60
PaO2 Threshold: 180 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
96.23
Sensitivity of ORI to Detect Drops in OxygenationPrimary· 1-5 hours
A measure of the ORI parameter's ability to detect changes in dissolved oxygen levels in blood plasma. Sensitivity, as measured in this outcome, is the probability of ORI dropping when there is a drop in blood oxygenation levels (desaturation).
PaO2 Threshold: 110 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
84.96
PaO2 Threshold: 120 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
89.85
PaO2 Threshold: 130 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
85.51
PaO2 Threshold: 140 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
89.47
PaO2 Threshold: 150 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
86.17
PaO2 Threshold: 160 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
87.13
PaO2 Threshold: 170 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
83.96
PaO2 Threshold: 180 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
85.40
Concordance of ORI to Detect Drops in OxygenationPrimary· 1-5 hours
A measure of the ORI parameter's ability to detect changes in dissolved oxygen levels in blood plasma. Concordance, as measured in this outcome, is the probability of ORI to respond accurately to changes (or lack of thereof) in underlying blood oxygenation levels. It is computed as a ratio of true classifications (true positives and true negatives) to the sample size. An ideal detector will have a concordance value of 1 (or 100%).
PaO2 Threshold: 110 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
88.83
PaO2 Threshold: 120 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
92.46
PaO2 Threshold: 130 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
91.47
PaO2 Threshold: 140 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
93.33
PaO2 Threshold: 150 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
93.00
PaO2 Threshold: 160 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
92.16
PaO2 Threshold: 170 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
90.80
PaO2 Threshold: 180 mmHg
Group
Value
95% CI
Oxygen Reserve Index (ORi) - RD Lite Sensors
93.78
Adverse events — posted to ClinicalTrials.gov
Time frame: 1 to 5 hours.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Oxygen Reserve Index (ORI) is a parameter that provides information on arterial partial pressure of oxygen (PaO2). In this study, the PaO2 is varied by controlling the concentration of oxygen the study volunteer breathes. The ORI device measurement is analyzed by comparing it to the PaO2 measurements from a laboratory analyzer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT06707207 — Predicting Future Errors During Skill Performance
· recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
· Phase 1
· recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease.
· NA
· recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects
· NA
· recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity
· Phase 1, PHASE2
· recruiting
Other Masimo Corporation trials
Trials by the same sponsor.
NCT07223177 — Philips FAST SpO2 Technology With Masimo Sensors for SpO2 Monitoring in the Neonatal, Infant, and Pediatric Populations
· NA
· recruiting
NCT07223164 — Validation of the Masimo Irregular Heartbeat Detection Algorithm in Participants Without Cardiovascular Disease
· NA
· recruiting
NCT06334055 — Validation Study of Mean Arterial Pressure (MAP) Parameter of Masimo INVSENSOR00073
· NA
· completed
NCT06432881 — Investigation of Skin Pigmentation Effect on Performance of Masimo Pulse Oximetry (INSPIRE)
· NA
· recruiting
NCT06148623 — Clinical Performance Testing of Philips FAST SpO2 With Masimo Pulse Oximetry Sensors Across Skin Pigmentation
· NA
· completed
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Masimo Corporation
Last refreshed: 1 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03128892.